Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D413282-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $64.90 | |
D413282-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $97.90 | |
D413282-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $220.90 | |
D413282-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $293.90 | |
D413282-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $489.90 |
HCV Protease Inhibitors
Synonyms | Dasabuvir|1132935-63-7|ABT-333|N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide|ABT333|Dasabuvir [INN]|Dasabuvir (ABT-333)|CHEBI:85182|ABT 333|Dasabuvir sodium monohydrate|N-(6-(3-tert-But |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fo |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Product Description | Information Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. |
ALogP | 3.492 |
---|---|
HBD Count | 2 |
Rotatable Bond | 6 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide |
---|---|
INCHI | InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31) |
InChi Key | NBRBXGKOEOGLOI-UHFFFAOYSA-N |
Canonical SMILES | CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O |
Isomeric SMILES | CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O |
PubChem CID | 56640146 |
Molecular Weight | 493.57 |
PubChem CID | 56640146 |
---|---|
CAS Registry No. | 1132935-63-7 |
ChEMBL Ligand | CHEMBL3137312 |
DrugBank Ligand | DB09183 |
DrugCentral Ligand | 4914 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2219458 | Certificate of Analysis | Jun 09, 2022 | D413282 |
G2219459 | Certificate of Analysis | Jun 09, 2022 | D413282 |
G2219460 | Certificate of Analysis | Jun 09, 2022 | D413282 |
G2219461 | Certificate of Analysis | Jun 09, 2022 | D413282 |
G2219462 | Certificate of Analysis | Jun 09, 2022 | D413282 |
Solubility | Solubility (25°C) In vitro DMSO: 98 mg/mL (198.55 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
Sensitivity | Moisture sensitive |
DMSO(mg / mL) Max Solubility | 98 |
DMSO(mM) Max Solubility | 198.553396681322 |
Water(mg / mL) Max Solubility | <1 |
Melt Point(°C) | >192ºC |
1. Stedman CA. (2013) Current prospects for interferon-free treatment of hepatitis C in 2012.. J Gastroenterol Hepatol, 28 (1): (38-45). [PMID:23137126] |